A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease
Status:
Not yet recruiting
Trial end date:
2030-01-01
Target enrollment:
Participant gender:
Summary
This clinical trial is a Phase 2/3 study that will determine the recommended dose of
mitapivat and evaluate the efficacy and safety of mitapivat in sickle cell disease by testing
how well mitapivat works compared to placebo to increase the amount of hemoglobin in the
blood and to reduce or prevent the occurrence of sickle cell pain crises. In addition, the
long-term effect of mitapivat on efficacy and safety will be explored in an open-label
extension portion.